"description","id","label","instanceType","name","uuid:ID","rationale"
"The main design for the study","StudyDesign_1","","StudyDesign","Study Design 1","83163bef-8ba6-41e2-a90c-7c831d3eecef","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
